

# Applications for Community Oncology

## Business of Oncology



October 9, 2025	Speaker(s)	Time (ET)
<b>Welcome &amp; Objectives</b>	<b>Cornerstone</b>	7:00 pm – 7:05 pm
<b>GS Panel Discussion: “Operationalizing NGS Testing – ROS1 Penetration Data”</b> <i>Nuvation Bio</i>	<b>Anna Vaysman, PharmD, BCPS</b> <i>Senior Director, Health Outcomes – Oncology; Nuvation Bio</i>	7:05 pm – 7:35 pm
<b>NGS testing – EGFR/HER2: Neo-Adjuvant, adjuvant &amp; metastatic</b> <i>Caris Life Sciences</i>	Tyler Mattox VP, Medical Affairs; Caris Life Sciences	7:35 pm – 8:05 pm
<b>Efficacy and Safety of Nivolumab and Relatlimab in Previously Untreated Advanced Melanoma, including an Indirect Treatment Comparison of First-Line Nivolumab and Relatlimab vs Nivolumab + Ipilimumab in Advanced Melanoma</b> <i>BMS</i>	<b>Jacob Brown</b> <i>Health Economics &amp; Outcomes Research Field Scientist; BMS</i>	8:05 pm – 8:50 pm
<b>Operationalizing BiSpecifics</b> <i>Regeneron</i>	<b>Speaker</b> Title	8:50 pm -9:20 pm
<b>Opdivo Qvantig presentation: Opdivo QvantigTM (nivolumab + hyaluronidase-nvhy) Subcutaneous Injection</b> <i>BMS</i>	<b>Alex Kaiser, PharmD, MS</b> <i>Director, Field Health Economics &amp; Outcomes Research; BMS</i>	9:20 pm – 9:35 pm
<b>Key Challenges Facing Community Oncology</b>	<b>Troy Simon</b> CEO, LA Cancer	9:35 pm – 10:05 pm
<b>Closing</b>	<b>Cornerstone</b>	10:05 pm – 10:10 pm